Mozobil (Plerixafor)

Plerixafor blocks the CXCR4 receptor, preventing its interaction with stromal‑derived factor‑1 (SDF‑1). This disruption releases stem cells from the bone‑marrow niche into the bloodstream, where they can be harvested for transplant. The mechanism enhances stem‑cell yield without directly affecting tumor cells.

The dose of Mozobil is determined by the prescribing clinician based on the patient’s weight, renal function, and the target stem‑cell collection goals. Dosing is individualized and administered under medical supervision; specific regimens are not disclosed here.

Safety data for plerixafor in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding decisions should be made in consultation with a healthcare professional.

To request Mozobil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

The primary alternative for stem‑cell mobilization is granulocyte‑colony stimulating factor (G‑CSF) such as filgrastim. G‑CSF stimulates stem‑cell release via a different pathway, while plerixafor directly antagonises CXCR4, often achieving faster and higher yields when used alone or in combination. Choice depends on patient factors, prior mobilization success and clinical protocol.

Mozobil must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

Mozobil is supplied as a sterile injection solution for subcutaneous administration. It is typically injected by a qualified healthcare professional into the abdomen or thigh, often in conjunction with G‑CSF. The injection site should be rotated and monitored for local reactions.

Serious adverse events include hypersensitivity reactions such as rash, urticaria or anaphylaxis, splenic rupture, and severe leukopenia that can predispose to infection. Patients should be monitored closely for signs of these conditions, and treatment should be stopped immediately if they occur.

Mozobil is contraindicated in individuals with known hypersensitivity to plerixafor or any excipients in the formulation. It should also be avoided in pregnant or nursing women unless the potential benefit outweighs the risk, and in patients with uncontrolled infections or severe organ dysfunction where stem‑cell mobilization is not advisable.